Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy

Camille C. Gunderson*, Sonia Dutta, Amanda Nickles Fader, Kruti P. Maniar, Niloo Nasseri-Nik, Robert E. Bristow, Teresa P. Diaz-Montes, Robert Palermo, Robert J. Kurman

*Corresponding author for this work

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Objective To determine the response of complex atypical hyperplasia (CAH) and well differentiated endometrioid adenocarcinoma of the uterus (WDC) to progestin therapy and whether pre-treatment estrogen and progesterone receptor status predicts outcome. Methods We performed a retrospective review encompassing women treated with progestin therapy for CAH or WDC at two institutions. Clinicopathologic, treatment, and recurrence data were recorded. Pre/post-treatment pathologic evaluation was performed. SAS 9.2 was used for statistical analyses. Results Forty-six patients were included. The median age was 35, and median BMI was 36.9. Thirty-seven percent were diagnosed with CAH and 63% had WDC. Megestrol acetate was the most commonly used agent (89%); 24% received multiple progestin therapies. Median treatment length was 6 months (range, 1-84); 36% of the patients underwent eventual hysterectomy, and 17.4% had carcinoma in their uterine specimens (8 primary endometrial, 1 primary ovarian). After a median follow-up of 35 months (range, 2-162), 65% experienced a complete response (CR), 28% had persistent or progressive disease, and 23% had a CR followed by recurrence. On univariate analysis, decreased post-treatment glandular cellularity (p = 0.0006), absence of post-treatment mitotic figures (p = 0.0008), and use of multiple progestin agents (p = 0.025) were associated with CR; however, only decreased glandular cellularity was significant on multivariate analysis (p = 0.007). Estrogen and progesterone receptor expression was not associated with treatment response. Conclusion In women with CAH or WDC, the overall response rate to progestin therapy was 65%; pre-treatment estrogen/progesterone receptor status did not predict response to treatment.

Original languageEnglish (US)
Pages (from-to)33-37
Number of pages5
JournalGynecologic oncology
Volume132
Issue number1
DOIs
StatePublished - Jan 1 2014

Keywords

  • Complex atypical hyperplasia
  • Estrogen/progesterone receptor
  • Progestin therapy
  • Well differentiated endometrial adenocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy'. Together they form a unique fingerprint.

  • Cite this

    Gunderson, C. C., Dutta, S., Fader, A. N., Maniar, K. P., Nasseri-Nik, N., Bristow, R. E., Diaz-Montes, T. P., Palermo, R., & Kurman, R. J. (2014). Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy. Gynecologic oncology, 132(1), 33-37. https://doi.org/10.1016/j.ygyno.2013.11.033